Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs |
| |
| Authors: | Dittmer Ulf Olbrich Anke R M |
| |
| Institution: | 1. State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, China;2. Shenzhen Institute of Translational Medicine, Health Science Center, Shenzhen Second People''s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China;3. University of Chinese Academy of Sciences, Beijing, 100190, China;4. Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, China;1. Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran;2. Department of Infectious Disease and Immunology, College of Veterinary Medicine, University of Florida, FL, USA;3. Technische Universität München & Helmholtz Zentrum München, Munich, Germany;4. Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;5. Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran;6. Department of Pathology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran;1. Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China;2. Department of Allergy and Immunology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China;1. VIM-INRA-Université Paris-Saclay, Domaine de Vilvert, 78350, Jouy-en-Josas, France;2. K.G. Jebsen Center for Research on Influenza Vaccines, University of Oslo and Oslo University Hospital, 0027, Oslo, Norway;3. Center for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, 0424, Oslo, Norway;4. Institute of Microbiology of the Czech Academy of Sciences, v.v.i., 142 20, Prague, Czech Republic;5. MI-mAbs, Parc Scientifique et Technologique de Luminy, Case 906, F13288, Marseille Cedex 9, France;6. Centre d’Immunologie de Marseille-Luminy, Aix Marseille Université UM2, Inserm, U1104, CNRS UMR7280, 13288, Marseille, France;1. Division of Biotechnology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran;2. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;3. Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran;4. Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;5. Immunology Section, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran |
| |
| Abstract: | Bacterial DNA with CpG motifs can efficiently stimulate the vertebrate immune system. Thus, synthetic oligodeoxynucleotides that contain such CpG motifs (CpG-ODN) are currently used in preclinical and clinical studies to develop new allergy or cancer therapies and vaccine adjuvants. Recent animal studies indicate that CpG-ODN therapies can also be used for successful treatment of infections caused by bacteria, parasites or viruses. In these experiments, innate and adaptive immune responses against pathogens were augmented by CpG-ODN and subsequently induced resistance against infectious diseases. The stimulation of dendritic cells played a central role for the therapeutic effect of CpG-ODN. However, CpG-ODN can also have negative side effects, which accelerate disease progression in some viral infections. Clinical studies with CpG-ODN will determine their potential for the therapy of infectious diseases in humans. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
